The biotech giant has reiterated its full-year Covid-19 vaccine revenue forecast of $21bn, despite cancelled orders from low and middle income nations via the COVAX programme offsetting gains from rising booster dose orders.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.